InVirtuoLabs

InVirtuoLabs is an innovative company focused on transforming drug discovery processes through its advanced artificial intelligence platform and molecular simulation technologies. InVirtuoLabs, founded in 2024 in Lugano, Switzerland, is dedicated to enhancing drug discovery via AI-driven molecular simulations. The company recently closed its first deal and has raised a total of EUR 2. 85 mn to date, with the latest funding round occurring on 20 February 2025.

The founder has experience in the industry, having previously initiated other ventures, although specific details of those companies are not available. InVirtuoLabs specializes in revolutionizing drug discovery through a proprietary platform that integrates advanced artificial intelligence with molecular simulations. Their core product offerings include a Molecular ML engine, a Multimodal generative AI module, and a Physics-based simulations workflow. These products work synergistically to facilitate rapid identification and optimization of promising drug candidates by evaluating a comprehensive range of critical molecular properties and generating novel drug-like molecules tailored to specific therapeutic targets.

The end users of these technologies include pharmaceutical companies and research institutions that aim to accelerate their drug discovery processes. InVirtuoLabs operates in various geographical markets, including North America, Europe, and Asia, where they cater to clients seeking innovative solutions in drug design and development. InVirtuoLabs generates revenue primarily through strategic partnerships and licensing agreements with pharmaceutical companies and research organizations. Their business model involves subscription-based access to their advanced platforms, allowing clients to utilize the tools for ongoing drug discovery projects.

The transactions typically structure around multi-year contracts that provide clients with comprehensive access to their suite of services, including the flagship programs like InVirtuoMOL, InVirtuoGEN, and InVirtuoSIM. Pricing plans are tailored to the specific needs of clients, often based on the scale of usage and the depth of integration required for their drug discovery initiatives. This structured approach facilitates ongoing collaboration and aligns the company's revenue growth with the success of its clients in bringing new therapies to market. In February 2025, InVirtuoLabs raised EUR 2.

85 mn in venture funding from unspecified investors. The company will use the funding to expand its AI-powered drug discovery platform, strengthen its team, initiate collaborations, and accelerate the development of new therapies, particularly for rare diseases. Plans for future growth include designing new products tailored to emerging therapeutic areas, with targeted launches anticipated within the next 18 months. Additionally, InVirtuoLabs aims to expand its presence in the North American and Asian markets by the end of 2026, capitalizing on the growing demand for advanced drug discovery solutions.